insights_auto
Waarom is ALNOV gestegen 4,65%?
Meer informatiechevron_right
ALNOV:EPA
Novacyt
€ 0,45
arrow_upward
+4,65%(+0,020) 1D
13 nov, 17:35:28 GMT+1 · EUR
search
Alle symbolen
| Symbool | Prijs | Wijziging | Wijzigingspercentage |
|---|
insights_autoBelangrijkste inzichten voor ALNOV genereren…
Openen
€ 0,44
Hoog
€ 0,46
Laag
€ 0,43
Beursw.
30,13 mln.
Gem. vol.
164,75K
Volume
156,80K
52 wk hoog
€ 1,04
52 wk laag
€ 0,29
WPA
€ -0,38
Uitstaande aandelen
72,59 mln.
Aantal medewerkers
228
Openen
€ 0,44
Hoog
€ 0,46
Laag
€ 0,43
Beursw.
30,13 mln.
Gem. vol.
164,75K
Volume
156,80K
52 wk hoog
€ 1,04
52 wk laag
€ 0,29
WPA
€ -0,38
Uitstaande aandelen
72,59 mln.
Aantal medewerkers
228
Nieuwsartikelen
Van webbronnen en nieuwspartners
Proactive financial news
·
2 dagen geleden
Novacyt shares rise over 6% after Australian approval for chemotherapy toxicity test
Profiel
Novacyt Group is an Anglo-French biotechnology group focused on clinical diagnostics, with offices in Camberley, Surrey, United Kingdom and Vélizy-Villacoublay, France. The company produces in vitro and molecular diagnostic tests, supplying assays and reagents worldwide. Its business units include Primerdesign, Microgen Bioproducts and Lab21 Healthcare.
In January 2020 the company announced that its molecular diagnostics division, Primerdesign, had launched a molecular test for the 2019 strain of SARSr-CoV. The test was approved as eligible for procurement under the World Health Organization's Emergency Use Listing process in April 2020, meaning that the test could be supplied by the United Nations and other procurement agencies supporting the COVID-19 response. In the same month Novacyt announced a collaboration with AstraZeneca, GlaxoSmithKline and the University of Cambridge to support the UK in its COVID-19 national screening programme at a new testing laboratory at the university's Anne McLaren laboratory. Wikipedia
Over Novacyt
CEODavid Allmond
Medewerkers228
Opgericht3 jul 2006
Hoofdkantoor-
SectorHealth Care
Industrie-
Websitenovacyt.com